Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Dec
10
2019
FDA Issues Warning Letters to 15 Companies, Consumer Update on CBD Safety Sheppard, Mullin, Richter & Hampton LLP
Jul
14
2023
FDA Releases Final Guidance on Quantitative Efficacy and Risk Information in Direct-to-Consumer Promotional Labeling and Advertisements Sheppard, Mullin, Richter & Hampton LLP
Apr
15
2020
FCPA Landmines Beneath the Surface of the COVID-19 Crisis - May 6 Sheppard, Mullin, Richter & Hampton LLP
Jul
31
2023
UCB, Inc. v. Actavis Laboratories UT, Inc. No. 2021-1924, (Fed. Cir. Apr. 12, 2023) Sheppard, Mullin, Richter & Hampton LLP
May
5
2020
IP Protection and the Open COVID Cure Chase Sheppard, Mullin, Richter & Hampton LLP
Sep
1
2023
Reclassifying Cannabis as a Schedule III Substance – Will the DEA Agree? Sheppard, Mullin, Richter & Hampton LLP
Oct
11
2023
The U.S. Department of Labor Provides Guidance for Agricultural Employers on the PUMP Act Sheppard, Mullin, Richter & Hampton LLP
Oct
20
2020
California Governor Pulls the Plug on Genetic Information Privacy Act Sheppard, Mullin, Richter & Hampton LLP
Mar
29
2021
FDA Announces First Ever Facility Fees for OTC Drug Manufacturers Sheppard, Mullin, Richter & Hampton LLP
Apr
15
2021
Breaking Down FDA’s New Remote Monitoring Strategy Sheppard, Mullin, Richter & Hampton LLP
Apr
26
2013
Delaware Supreme Court Affirms Preclusive Effect of Non-Delaware Dismissals and Rejects Irrebuttable Presumption That a Derivative Plaintiff Who Fails to Conduct a Section 220 Inspection Is an Inadequate Representative Sheppard, Mullin, Richter & Hampton LLP
May
2
2013
Can California Cap and Trade if Brussels Stumbles? Sheppard, Mullin, Richter & Hampton LLP
Apr
13
2018
Health Plans and Pharmacy Benefit Managers – Past and Future Sheppard, Mullin, Richter & Hampton LLP
Sep
27
2013
Details: Highlights from the August & September 2013 Federal Register Sheppard, Mullin, Richter & Hampton LLP
Sep
22
2021
Elijah E. Cummins Lower Drug Costs Now Act: The Long and Winding Road to Drug Pricing Reform Sheppard, Mullin, Richter & Hampton LLP
Nov
29
2018
CMS Issues Proposed Rule on Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses Sheppard, Mullin, Richter & Hampton LLP
Nov
22
2021
FDA Joins Other Regulators in Focus on AI and Machine Learning Sheppard, Mullin, Richter & Hampton LLP
Apr
26
2014
Preexisting Management Plan Not a “Mitigation Measure” for Purposes of California Environmental Quality Act (CEQA) Exemption Sheppard, Mullin, Richter & Hampton LLP
Mar
29
2019
OH SNAP! Supreme Court to Take on Meaning of Key FOIA Exemption Sheppard, Mullin, Richter & Hampton LLP
Mar
24
2022
HHS OIG Signs Off on Substance Use Recovery Incentive Program Sheppard, Mullin, Richter & Hampton LLP
Oct
24
2014
FTC Takes Action Against Unsubstantiated Caffeine-Infused Shapewear Weight-Loss Claims Sheppard, Mullin, Richter & Hampton LLP
Mar
4
2015
Ascertainability Saps Plaintiffs’ Energy in Dietary Supplement Class Action Sheppard, Mullin, Richter & Hampton LLP
Sep
15
2022
California Expands FEHA to Include Off The Job Cannabis Use Sheppard, Mullin, Richter & Hampton LLP
Oct
31
2022
CMS Heightens Oversight of TPMO Marketing Programs, Restricts TV Advertisements Sheppard, Mullin, Richter & Hampton LLP
Dec
6
2022
Don’t Let Drugs Bring You Down: The Importance of an Effective Drug Diversion Program Sheppard, Mullin, Richter & Hampton LLP
Jan
7
2020
FDA Year in Review: A Shifting Regulatory Landscape Sheppard, Mullin, Richter & Hampton LLP
Mar
5
2020
Nota Bene Episode 71: Shifting Regulatory Landscapes at the FDA: Cannabis, Vaping and Intelligent Medical Devices with Allison Fulton [PODCAST] Sheppard, Mullin, Richter & Hampton LLP
Mar
10
2020
Prop 65 Warnings and Acrylamide in Food – Can I Still Have My Coffee and Drink it Too? Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins